Table 1.

Baseline Patient Characteristics for the Whole Population

Demographic variable	All subjects (n=3739)	Female subjects (n=1051)	Male subjects (n=2688)	P value
Age (y)
Mean±SD	68±11	68±11	68±11	0.3454*
NYHA class at enrollment (%)
Class II	51.2	45.3	53.5
Class III	46.6	52.1	44.5	<0.0001†
Class IV	1.9	2.4	1.7
QRS duration (ms)
Mean±SD	156±25	153±22	158±26	<0.0001*
QRS morphology (%)
LBBB	70.2	79.5	66.4	<0.0001†
Non‐LBBB	29.8	20.5	33.6
Cardiomyopathy cause (%)
Ischemic	41.0	22.0	48.4	<0.0001†
Nonischemic	59.0	78.0	51.6
LVESV (mL)
Mean±SD	160±65	131±52	171±66	<0.0001*
LVEDV (mL)
Mean±SD	214±76	176±60	228±77	<0.0001*
LVEF (%)
Mean±SD	26±7	27±7	26±7	0.0965*
Device type (%)
CRT‐P	12.2	16.9	10.4	<0.0001†
CRT‐D	87.8	83.1	89.6
Medical history (%)
Hypertension	62.3	59.0	63.6	0.0087†
Hypercholesterolemia	40.1	34.6	42.4	<0.0001†
Diabetes	33.4	30.4	34.6	0.0126†
COPD	10.6	8.5	11.5	0.0076†
Renal disease	15.0	11.4	16.4	0.0001†
Medical treatment (%)
Diuretics	77.4	79.5	76.5	0.0474†
ACE inhibitor/ARB	89.3	89.4	89.2	0.8400†
β‐Blocker	89.1	89.2	89.1	0.8697†
Aldosterone antagonist	38.9	38.5	39.1	0.7660†
Anticoagulant	26.9	21.4	29.1	<0.0001†
Calcium channel blocker	7.9	6.2	8.6	0.0156†
Nitrates	7.4	5.6	8.1	0.0097†

ACE indicates angiotensin‐converting enzyme; ARB, angiotensin receptor blocker; COPD, chronic obstructive pulmonary disease; CRT‐D, cardiac resynchronization therapy with defibrillator; CRT‐P, cardiac resynchronization therapy without defibrillator; LBBB, left bundle‐branch block; LVEDV, left ventricular end‐diastolic volume; LVEF, left ventricular ejection fraction; LVESV, left ventricular end‐systolic volume; and NYHA, New York Heart Association.

^*Wilcoxon rank sum test.

^†Pearson χ² test.